Half-life
Not well-established; estimated hours based on thymosin beta-4 data
Evidence Level
Preliminary
Mechanism of Action
Sequesters actin monomers, promotes cell migration, upregulates metalloproteinases for ECM remodeling, and possesses anti-inflammatory properties via NF-κB pathway modulation.
Published Research Ranges & Study Context
Studies have administered: 2–10mg weekly in published research protocols
Important Research Framing
These are ranges reported in published scientific studies. They are provided for educational context only and do not constitute dosing recommendations. Individual study parameters vary by design, population, and research objectives. This information is not medical advice.
Primary Research Findings
Animal studies show cardiac protection post-MI, wound healing acceleration, and neurological recovery. Phase 2 cardiac trials conducted. Equine veterinary research extensive.
Preliminary
Primarily preclinical + case reports
Side Effects Observed in Research
Generally well-tolerated; injection site reactions; rare flu-like symptoms in human reports
Available Configurations (SKU Reference)
TB5
TB10
Compounds Studied in Combination
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on TB-500 — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat
Research Education Only: This compound profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions. Regulatory status varies by jurisdiction.